Cardio Diagnostics Holdings, Inc. to hold investor call on Wednesday, February 18, 2026

Cardio Diagnostics Holdings, Inc. is gearing up to host an investor conference call on February 18, 2026, aiming to shed light on its precision cardiovascular medicine strategies. The company, listed on Nasdaq under the ticker symbol CDIO, specializes in leveraging epigenetics, genetics, and artificial intelligence to prevent and detect cardiovascular diseases efficiently.

The upcoming call scheduled for 3 p.m. Central Time will delve into Cardio Diagnostics’ detailed molecular approach towards averting and spotting cardiovascular issues early. Investors can expect updates on the company’s available tests, including Epi+Gen CHD™ and PrecisionCHD™, along with recent clinical data milestones, reimbursement advancements, and strategic growth maneuvers.

Cardio Diagnostics prides itself on being an artificial intelligence-powered firm that revolutionizes cardiovascular disease prevention, detection, and management by tailoring approaches to individual needs accurately. Equipped with a cutting-edge Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine as its cornerstone technology, the company aims to streamline cardiovascular health solutions.

Shaping the future landscape of healthcare, Cardio Diagnostics has been instrumental in making personalized cardiovascular care more accessible than ever before. With a primary focus on enhancing clinical tests through innovative technologies, the company is committed to improving the overall cardiovascular healthcare landscape.

Bringing a fresh perspective to the realm of cardiovascular medicine, Cardio Diagnostics stands as a beacon of hope for enhanced patient outcomes. By intertwining science, technology, and compassion, the company has positioned itself as a frontrunner in the realm of precision medicine.

Embarking on a journey towards revolutionary healthcare advancement, Cardio Diagnostics remains at the forefront of cardiovascular medicine. Through cutting-edge advancements in epigenetics, genetics, and artificial intelligence, the company is setting new benchmarks in the prevention and detection of cardiovascular diseases.

Looking ahead with a sense of optimism and determination, Cardio Diagnostics is poised to redefine cardiovascular healthcare solutions. By melding innovation with compassion, the company continues to pave the way towards better cardiovascular health outcomes for individuals.

As the world of healthcare continues to evolve, Cardio Diagnostics remains steadfast in its commitment to leveraging technology for the betterment of cardiovascular health. With a bold vision and unwavering dedication, the company seeks to usher in a new era of precision medicine that prioritizes patient-centric care.

In conclusion, Cardio Diagnostics’ investor call on February 18, 2026, promises to be a window into the company’s groundbreaking strategies for precision cardiovascular medicine. With a relentless focus on innovation, patient care, and technological advancements, Cardio Diagnostics is poised to make a significant impact on the future of cardiovascular healthcare.